Changes in Iron Metabolism and Oxidative Status in STZ-Induced Diabetic Rats Treated with Bis(maltolato) Oxovanadium (IV) as an Antidiabetic Agent

Table 2

Iron content in kidney, liver, spleen, muscle, heart, and femur (mg/kg dry tissue) on day 35.

	C	DM	DMV	DMVH	𝑃test
Kidney	255 ± 43	359 ± 74^a	299 ± 51	290 ± 53	𝑃<0.05
Liver	404 ± 54	428 ± 65	505 ± 82^a,b	530 ± 73^a,b	𝑃<0.05
Spleen	3043 ± 646	1849 ± 718^a	2410 ± 670	3918 ± 671^a,b,c	𝑃<0.001
Muscle	50 ± 14	68 ± 19^a	70 ± 14^a	46 ± 5^b,c	𝑃<0.01
Heart	340 ± 26	353 ± 56	356 ± 44	420 ± 46^a,b,c	𝑃<0.05
Femur	40 ± 4	61 ± 4^a	69 ± 6^a,b	64 ± 19^a	𝑃<0.001

Values shown are means ± SD, C: control rats; DM: diabetic STZ rats; DMV: diabetic STZ rats treated with 1 mgV/day; DMVH: diabetic STZ rats treated with 3 mgV/day. ^aDifferent from group C; ^bdifferent from group DM; ^cdifferent from group DMV. 𝑃<0.05.